Avantor, Inc. (NYSE:AVTR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Avantor, Inc. (NYSE:AVTR) have earned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $27.40.

A number of equities analysts have issued reports on the company. Wells Fargo & Company assumed coverage on Avantor in a report on Tuesday, August 27th. They set an “overweight” rating and a $30.00 target price on the stock. Stifel Nicolaus boosted their price objective on shares of Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a report on Monday, July 29th. Barclays increased their target price on shares of Avantor from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. TD Cowen upped their price objective on shares of Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 29th. Finally, Morgan Stanley raised their price objective on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th.

Insider Transactions at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Avantor

A number of institutional investors and hedge funds have recently made changes to their positions in AVTR. Jennison Associates LLC raised its position in Avantor by 113.0% during the first quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock worth $63,857,000 after acquiring an additional 1,325,026 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Avantor by 146.1% during the fourth quarter. BNP Paribas Financial Markets now owns 217,296 shares of the company’s stock worth $4,961,000 after purchasing an additional 129,010 shares during the period. Swedbank AB acquired a new position in Avantor during the first quarter worth approximately $2,707,000. Diversify Advisory Services LLC bought a new stake in Avantor in the first quarter valued at approximately $908,000. Finally, CenterBook Partners LP acquired a new stake in shares of Avantor in the fourth quarter valued at approximately $4,562,000. Institutional investors own 95.08% of the company’s stock.

Avantor Stock Down 1.5 %

Shares of NYSE:AVTR opened at $26.58 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. The stock has a market cap of $18.05 billion, a price-to-earnings ratio of 68.15, a P/E/G ratio of 2.75 and a beta of 1.32. The company has a 50 day moving average of $25.16 and a 200-day moving average of $24.36. Avantor has a one year low of $16.63 and a one year high of $28.00.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Friday, July 26th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. Avantor had a return on equity of 12.40% and a net margin of 5.28%. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.70 billion. On average, sell-side analysts forecast that Avantor will post 1.01 earnings per share for the current year.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.